German study shows clinical benefit of NevisenseApril 29, 2022
STOCKHOLM, SWEDEN, - April 29, 2022 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new study published this week in Germany demonstrated the clinical benefits of Nevisense in day-to-day practice. The study titled - "Electrical Impedance Spectroscopy Improves Skin Cancer Detection and Reduces the Number of Biopsies" and authored by Dr Liebich et al was published online in the journal Dermato.
SciBase publishes the Annual report for 2021April 22, 2022
SciBase hereby announces that the Annual report for 2021 is available at the Company's website www.scibase.com.
SciBase further strengthens patent portfolioMarch 30, 2022
STOCKHOLM, SWEDEN, — March 30, 2022 – SciBase Holding AB (“SciBase”) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that its patent application : EP Application No. 18729063.0 has been granted by EPO in Europe. This patent is linked to the new measurement procedure instituted recently with the introduction of Nevisense 3.0.
- Load more news...